Publication

Article

Pharmaceutical Executive

Pharmaceutical Executive-03-01-2022
Volume42
Issue 3

Pharmaceutical Executive, March 2022 Issue (PDF)

Download Issue PDF
Articles in this issue
Pressed Into Action: Measuring Pharma’s Reputation Reversal
Pressed Into Action: Measuring Pharma’s Reputation Reversal
Biopharma in 2021: Big Gains, Volatile Values
Biopharma in 2021: Big Gains, Volatile Values
The Resilience of R&D: Pharma Posted Record Output in 2021
The Resilience of R&D: Pharma Posted Record Output in 2021
A Complex Patent & Pricing Picture: Regulating Psychedelics More of a Journey Than a Trip
New Age of Psychedelics
New Age of Psychedelics
Roads Less Traveled
Roads Less Traveled

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!
Related Videos
Dr. Harshit Jain
Related Content
Stock.adobe.com
August 30th 2025

Santersus AG Announces FDA Granted NucleoCapture Breakthrough Device Designation

Nicholas Jacobus
The Rx for High-Performance Leadership: Cutting Through the Chaos
August 30th 2025

The Rx for High-Performance Leadership: Cutting Through the Chaos

Michael Christel
Stock.adobe.com
August 30th 2025

Outlook Therapeutics Receives CRL for BLA Resubmission of Lytenava

Nicholas Jacobus
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
August 30th 2025

Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research

Miranda Schmalfuhs
Stock.adobe.com
August 30th 2025

Replicate Bioscience Announces Partnership with Novo Nordisk Aimed at Unlocking Self-Replicating RNA Therapies

Nicholas Jacobus
Stock.adobe.com
August 30th 2025

Amylyx Pharmaceuticals Discontinues Orion Program of Ax0035

Nicholas Jacobus